Jacked on JAKs: The Therapeutic Impact of Dose Escalation in a Case of Refractory Atopic Dermatitis
Case author Graham Litchman, DO, MS, presents a case of a young adult patient with longstanding atopic dermatitis that remained uncontrolled despite multiple prior therapies, prompting consideration of dose escalation with a JAK inhibitor.
By Graham Litchman, DO, MS
Case Presentation and Medical History
A 25-year-old Hispanic male with a longstanding history of moderate-to-severe atopic dermatitis presented with progressive worsening of his condition over the past year. Despite adherence to standard therapies, including topical corticosteroids, topical calcineurin inhibitors, dupilumab, and upadacitinib at both 15 mg and 30 mg doses, his disease remained poorly controlled. The patient, a bodybuilder with a strong commitment to physical health and nutrition, expressed considerable frustration over the lack of improvement despite optimizing lifestyle and medical management.
Given the refractory nature of his disease, oral abrocitinib was initiated at 100 mg daily. Partial improvement was observed, but flares persisted, prompting escalation to 200 mg daily. At this dose, the patient experienced complete clearance and expressed a marked improvement in quality of life.
After 3 months of stable disease control, a trial dose reduction back to 100 mg daily was attempted, and remission was maintained for another 3 months. However, following occupational exposure to a new cleaning chemical, the patient experienced a flare. The dose of abrocitinib was increased back to 200 mg daily, leading once again to full clearance.
Physical Examination and Laboratory Findings
On initial presentation, the patient exhibited ill-defined erythematous patches involving the forehead and temple region, extending into the upper cheek. Additional involvement was noted on the medial thigh, where there were ill-defined erythematous patches with excoriations, consistent with atopic dermatitis. No systemic abnormalities were noted. Laboratory studies, including a complete blood count and comprehensive metabolic panel, were within normal limits.
Diagnostic Review
This case highlights several important diagnostic considerations. A patient with longstanding, refractory dermatitis must be carefully evaluated to rule out alternative or overlapping diagnoses, such as chronic contact dermatitis or, in rare instances, cutaneous T-cell lymphoma. Occupational exposures were relevant in this case as a flare trigger but not the primary driver of disease.
When initiating oral abrocitinib for the treatment of atopic dermatitis, what is the appropriate approach to dose escalation?
Before & After Photos
Treatment Discussion and Outcome
In this patient, abrocitinib was chosen as the next-line systemic therapy given its distinct JAK1 selectivity and the lack of adequate disease control on both dupilumab and upadacitinib. Treatment considerations included efficacy, safety, adherence, and the potential for dose optimization. The robust response to 200 mg daily demonstrated clear efficacy, while the attempt at de-escalation reflected an effort to balance control with minimizing drug exposure. The subsequent flare after chemical exposure highlighted the role of environmental triggers in disease activity but also confirmed the dose-responsive nature of abrocitinib, as full clearance was rapidly regained on re-escalation.
A common pitfall in similar presentations is prolonged reliance on topical therapy despite evidence of systemic disease burden, or delay in escalating to advanced systemic treatments when biologics or earlier systemic options fail. This case underscores the importance of considering mechanistically distinct systemic therapies when patients fail to achieve disease control with available biologics.
Ultimately, the patient achieved durable disease control on abrocitinib 200 mg daily with significant improvement in quality of life and restoration of physical comfort.
Conclusion
This case illustrates the challenges of managing refractory atopic dermatitis in a young adult and demonstrates the clinical value of abrocitinib in achieving control after multiple prior treatment failures. It reflects the importance of individualized treatment planning, careful dose adjustment, and ongoing attention to environmental and occupational triggers. For dermatologists, this case reinforces the need to remain flexible in therapeutic sequencing and to consider alternative mechanisms of action when conventional and biologic therapies fail.